Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

Stent, urethral, prostatic, semi-permanent

PMA Number: P060010 · 2022-10-07

ApplicantSrs Medical
Decision Date2022-10-07
PMA NumberP060010
Product CodeNZC
Device ClassClass 3
Medical SpecialtyU
Advisory CommitteeGU

Device Summary

Stent, urethral, prostatic, semi-permanent is a medical device manufactured by Srs Medical. It received FDA Premarket Approval (PMA) on 2022-10-07 under PMA number P060010. The device is classified under FDA product code NZC. It was reviewed by the GU advisory panel. This device is classified as Class III by the FDA. Class III devices subject to the most stringent regulatory controls. These devices generally require premarket approval (PMA) because they support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. PMA is the most stringent type of device marketing application required by the FDA. The device falls under the medical specialty of U. Unlike 510(k) clearance, which demonstrates substantial equivalence to a predicate device, PMA requires the manufacturer to submit clinical trial data demonstrating the safety and effectiveness of the device. PMA is generally required for Class III devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury.

Frequently Asked Questions

What is Stent, urethral, prostatic, semi-permanent?

Stent, urethral, prostatic, semi-permanent is a medical device that received FDA Premarket Approval (PMA) on 2022-10-07. It is manufactured by Srs Medical. The PMA number is P060010.

When did Stent, urethral, prostatic, semi-permanent receive FDA PMA approval?

Stent, urethral, prostatic, semi-permanent received FDA PMA approval on 2022-10-07, under approval number P060010.

What company makes Stent, urethral, prostatic, semi-permanent?

Stent, urethral, prostatic, semi-permanent is manufactured by Srs Medical.

What is the difference between PMA and 510(k)?

PMA (Premarket Approval) is the FDA process for evaluating Class III medical devices. Unlike 510(k) clearance, which demonstrates substantial equivalence to a predicate device, PMA requires the manufacturer to provide clinical data proving safety and effectiveness. PMA is the most stringent type of device marketing application required by the FDA.

What is the FDA product code for Stent, urethral, prostatic, semi-permanent?

The FDA product code for Stent, urethral, prostatic, semi-permanent is NZC.

What FDA device class is Stent, urethral, prostatic, semi-permanent?

Stent, urethral, prostatic, semi-permanent is classified as Class III by the FDA.

Related Clinical Trials

Other Devices by Srs Medical

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.